Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 6/20 | 0.53 |
| ▸ | RXRB | P28702 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583263 | 0.84 | ALDH1A1 (0.59) | NPC1RAB9ALMNA | |
| SCHEMBL17572267 | 0.79 | GAA (0.60) | GAANR4A2NR4A1NR4A3RXRA | |
| SCHEMBL583043 | 0.79 | PPARD (0.52) | POLBPKMPPARD | |
| SCHEMBL28000922 | 0.78 | LMNA (0.50) | SMN1; SMN2LMNA | |
| SCHEMBL583036 | 0.77 | CA12 (0.56) | RXRARAB9ALMNA | |
| SCHEMBL583633 | 0.77 | HTT (0.61) | RXRANPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL13179825 | 0.76 | MRGPRX4 (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28237053 | 0.75 | LMNA (0.48) | LMNAPPARD | |
| SCHEMBL27718621 | 0.74 | P2RX3 (0.67) | GAANR4A1POLBSMN1; SMN2SRD5A2 | |
| SCHEMBL3336565 | 0.74 | PKM (0.62) | NR4A2NR4A1NR4A3RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | claimed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | claimed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | claimed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | claimed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | disclosed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | AHR, CYP3A5, CYP3A43 | GAA 2636/4885NR4A2 86/4885NR4A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.